A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Participants must have measurable disease as defined by RECIST 1.1 criteria

Participants must have evidence of a defect in the PI3K/AKT pathway, defined by A) evidence of loss of PTEN by immunohistochemistry in a CLIA-certified assay or B) documentation of PIK3CA or AKT mutation in a CLIA-certified assay; for patients without prior CLIA-certified evidence of a PI3K/AKT pathway defect, PTEN testing will be performed by immunohistochemistry in a CLIA-certified assay; availability of a formalin fixed paraffin embedded (FFPE) block of cancer tissue from the original or most recent biopsy must be available for mutational and immunohistochemical analysis

Prior therapy:

* Prior chemotherapy must have included a first-line platinum-based regimen with or without consolidation chemotherapy

* Patients may have received up to 2 lines of therapy (including cytotoxic or biological and/or targeted therapies) in the recurrent setting

* Prior hormonal therapy is acceptable and will not count as an additional line of therapy

* Patients may not have previously received prior AKT or PI3 kinase pathway inhibitors (including mTOR inhibitors)

* Patients should have platinum-resistant disease, where platinum resistance is defined as having progressive disease within 6 months of receipt of prior platinum therapy

Life expectancy of greater than 6 months

Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky \> 60%)

Absolute neutrophil count \>= 1,500/mcL

Platelets \>= 100,000/mcL

Hemoglobin \>= 8.0 g/dL

Total bilirubin within normal institutional limits

Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) \< 2.5 X institutional upper limit of normal

Creatinine within normal institutional limits or creatinine clearance \> 60 mL/min/1.73 m\^2 for subjects with creatinine levels about institutional normal

Toxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per NCI-CTCAE v4.0

Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of MK-2206

The effects of MK-2206 on the developing human fetus are unknown; for this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

Ability to understand and the willingness to sign a written informed consent document

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with MK-2206; iIn addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

Patients may not use natural herbal products or other "folk remedies" while participating in this study

What this study is about